EMA/706562/2010

European Medicines Agency decision

P/233/2010

of 26 November 2010

on the acceptance of a modification of an agreed paediatric investigation plan for clopidogrel (Plavix) (EMEA-000049-PIP01-07-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/233/2010

of 26 November 2010

on the acceptance of a modification of an agreed paediatric investigation plan for clopidogrel (Plavix) (EMEA-000049-PIP01-07-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/25/2008 issued on 23 May 2008, and the decision P/122/2008 issued on 05 December 2008,

Having regard to the application submitted by Sanofi Pharma Bristol-Myers Squibb SNC on 19 July 2010 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 October 2010, in accordance with Article 22 of Regulation (EC) No 1901/2006, and of its own motion in accordance with Article 12 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision on the granting of a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for clopidogrel (Plavix), oral formulation, film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A waiver for clopidogrel (Plavix), oral formulation, film-coated tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Sanofi Pharma Bristol-Myers Squibb SNC, 174 avenue de France, 75013 Paris, France.

Done at London, 26 November 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

EMA/605247/2010

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000049-PIP01-07-M03

Scope of the application

Active substance(s):

Clopidogrel

Invented name:

Plavix

Condition(s):

Prevention of thromboembolic events

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Oral formulation

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Sanofi Pharma Bristol-Myers Squibb SNC

Information about the authorised medicinal product: see Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Sanofi Pharma Bristol-Myers Squibb SNC submitted to the European Medicines Agency on 19 July 2010 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/25/2008 issued on 23 May 2008, and the decision P/122/2008 issued

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

on 05 December 2008.
The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 August 2010.

A meeting with the Paediatric Committee took place on 06 October 2010.

Scope of the modification

A measure of the original opinion was removed and the waiver has been modified to include a new paediatric subset.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion,
   - to grant a waiver for one or more subsets of the paediatric population on its own motion in accordance with Article 12 of said Regulation and concluded in accordance with
     - Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 08 October 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Prevention of thromboembolic events

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
- for oral formulation, film-coated tablet; oral use
- for prevention of atherothrombotic events
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- The paediatric population from 2 years to less than 18 years
- for oral formulation, film-coated tablet; oral use
- for prevention of thromboembolic events
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric Investigation Plan

2.1. Condition: Prevention of thromboembolic events

2.1.1. Indication(s) targeted by the PIP

Prevention of thrombosis and thromboembolic events in children at risk

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 2 years of age.

2.1.3. Pharmaceutical form(s)

Oral formulation, film-coated tablet

2.1.4. Studies

Area	Number of studies	Description
Clinical	4	Study 1: Open, cross-over, randomized, mono-centre bioequivalence study of the 75 mg tablet and 75 mg oral solution of clopidogrel after single oral administration to young healthy men* Study 2: Multi-centre, randomised, double-blind, placebo-controlled dose-finding study and pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in neonates and infants at risk for thrombosis

		Study 3: Randomised, multi-centre, double-blind, placebo-controlled efficacy and safety study of clopidogrel in neonates and infants with systemic-to-pulmonary artery shunt Study 4: Double-blind extension phase of study #3 for children aged 1 year and older

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2010
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of thromboembolic events

   Authorised indications:

   Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

   - Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
   - Patients suffering from acute coronary syndrome:
     - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
     - ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

EU Number	Invented name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/98/069/001a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	28 tablets
EU/1/98/069/001b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	28 tablets
EU/1/98/069/002a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	50 tablets
EU/1/98/069/002b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	50 tablets
EU/1/98/069/003a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	84 tablets
EU/1/98/069/003b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	84 tablets
EU/1/98/069/004a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	100 tablets
EU/1/98/069/004b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	100 tablets
EU/1/98/069/005a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	30 tablets
EU/1/98/069/005b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 tablets
EU/1/98/069/006a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	90 tablets
EU/1/98/069/006b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	90 tablets
EU/1/98/069/007a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	14 tablets
EU/1/98/069/007b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	14 tablets
EU/1/98/069/008	Plavix	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	4 x 1 tablets
EU/1/98/069/009	Plavix	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 x 1 tablets
EU/1/98/069/010	Plavix	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	100 x 1 tablets
EU/1/98/069/011a	Plavix	75 mg	Film-coated tablet	Oral use	blister (PVC/PVDC/alu)	7 tablets
EU/1/98/069/011b	Plavix	75 mg	Film-coated tablet	Oral use	blister (alu/alu)	7 tablets
EU/1/98/069/012	Plavix	300 mg	Film-coated tablet	Oral use	blister (alu/alu)	10x1 tablets